Background Treatment with elexacaftor/tezacaftor/ivacaftor (ETI) improves multiple clinical
outcomes in people with cystic fibrosis (pwCF) with at least one F508del allele. This study …

Background/Aims: In cystic fibrosis (CF), chronic microbial lung infections are difficult to treat
and cause morbidity and increased mortality. Methods: In a multicentre, open-label …

Objectives Pediatric lymphocytic interstitial pneumonia (LIP) and follicular bronchiolitis (FB)
are poorly characterized lymphoproliferative disorders. We present and quantify …

Background Children are commonly affected by respiratory tract infections. Based on clinical
symptoms, laboratory evaluation, and imaging, the causative pathogen often cannot be …

Background: In the primary and secondary prevention of civilization diseases, regular
physical activity is recommended in international guidelines to improve disease-related …

Background Regular participation in exercise is important for people with cystic fibrosis (CF).
Therefore, we implemented a personalized, web-based exercise intervention over the …

Background Impaired respiratory and intestinal microbiome composition is linked to cystic
fibrosis lung disease severity. In people with cystic fibrosis (pwCF), regular exercise is …

Introduction Massive haemoptysis is a life-threatening event in advanced cystic fibrosis (CF)
lung disease with bronchial artery embolisation (BAE) as standard of care treatment. The …

N-type tracheoesophageal fistula without atresia is a rare congenital tracheoesophageal
anomaly. Open surgical repair through a right cervical incision is the standard procedure in …

CFTR-modulator therapy, particularly the elexacaftor/tezacaftor/ivacaftor (ETI) combination,
revolutionizes cystic fibrosis (CF) treatment by enhancing CFTR protein function. Despite …